Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage



Status:Recruiting
Healthy:No
Age Range:18 - 40
Updated:8/29/2018
Start Date:September 18, 2017
End Date:August 2020
Contact:Lindsey S Palm, BS
Email:lpalm@ufl.edu
Phone:727-373-8104

Use our guide to learn which trials are right for you!

Erythritol is a low calorie sugar substitute that is being increasingly used to sweeten
beverages and other food items. Greater amounts of erythritol are required to reach the
sweetness level of a common soft drink as compared to aspartame, resulting in higher
osmolarity for the erythritol sweetened beverage. Since associations have been noted between
osmolarity and satiety, investigators propose that an erythritol sweetened beverage may
enhance satiety more than a beverage sweetened with aspartame.

The effects of an erythritol sweetened beverage on satiety has yet to be specifically
explored. In this double-blind, 2-way crossover trial, healthy volunteers will consume one of
two beverages on each visit: either an erythritol sweetened beverage or an aspartame
sweetened beverage. Both beverages will be prepared to the same level of sweetness.

Timed blood samples will be collected over a period of two hours following consumption of the
sweetened beverage. Serum total ghrelin and serum insulin will be measured from all blood
samples. A validated hunger scale will be administered three times within the two hour
period. Data analysis for all measures will be reported with respect to deviation from the
initial baseline measured at time 0.

Inclusion Criteria:

- Healthy

- BMI below 25

- Maintained a stable body weight for at least three months prior to volunteering

Exclusion Criteria:

- Exclude if smoking, substance abuse, have a chronic medical or psychiatric illness,
regularly intake medications (except for oral contraceptives), regularly use
supplements besides vitamins/minerals, have a history of gastrointestinal or renal
disorders, have food allergies, have medical dietary restrictions, or have any
abnormalities detected on physical examination indicative of disease.

- Participants must have intact gastrointestinal and kidney function to adequately
absorb and eliminate the erythritol. Eligibility will be determined by self-reported
medical history, physical examination, and specific questioning to exclude prior renal
or Gastrointestinal disease after the informed consent process.

- Exclude if abnormal GI anatomy due to surgery (besides appendix removal) or congenital
defect as may impair ghrelin production.

- Exclude if the patient is pregnant, lactating, or planning to become pregnant as
erythritol has not been specifically tested in this population.

- Exclude if have a Body Mass Index over 25, as ghrelin as a marker of satiety may not
be accurate at high Body Mass Index.
We found this trial at
1
site
Gainesville, Florida 32610
Phone: 727-373-8104
?
mi
from
Gainesville, FL
Click here to add this to my saved trials